The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Independent characterization by duel staining of progesterone receptor (PR) and estrogen receptor (ER) in breast cancer (BC).
Alexander A. Zukiwski
Employment or Leadership Position - Arno Therapeutics
Consultant or Advisory Role - Invivis (U)
Stock Ownership - Arno Therapeutics
Jean-Michel Caillaud
No relevant relationships to disclose
Jacques Bosq
Consultant or Advisory Role - Invivis
Suzanne A. W. Fuqua
Consultant or Advisory Role - Arno Therapeutics
Carol A. Lange
Consultant or Advisory Role - Arno Therapeutics
Joyce O'Shaughnessy
Consultant or Advisory Role - Arno Therapeutics
Erard M. Gilles
Employment or Leadership Position - Invivis
Consultant or Advisory Role - Arno Therapeutics
Stock Ownership - Invivis
Jacques Bonneterre
No relevant relationships to disclose